Lee Danner & Bass Inc. Has $1.91 Million Stock Position in Danaher Co. (NYSE:DHR)

Lee Danner & Bass Inc. grew its holdings in shares of Danaher Co. (NYSE:DHR) by 138.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 8,238 shares of the conglomerate’s stock after acquiring an additional 4,784 shares during the period. Lee Danner & Bass Inc.’s holdings in Danaher were worth $1,906,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of DHR. Nicholas Hoffman & Company LLC. raised its stake in shares of Danaher by 2.3% during the 4th quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock valued at $439,000 after purchasing an additional 43 shares during the period. Drive Wealth Management LLC increased its position in shares of Danaher by 3.1% during the fourth quarter. Drive Wealth Management LLC now owns 1,485 shares of the conglomerate’s stock valued at $344,000 after buying an additional 44 shares during the period. Trust Investment Advisors lifted its holdings in shares of Danaher by 1.8% in the fourth quarter. Trust Investment Advisors now owns 2,811 shares of the conglomerate’s stock worth $650,000 after buying an additional 49 shares in the last quarter. New Hampshire Trust boosted its position in shares of Danaher by 0.3% in the third quarter. New Hampshire Trust now owns 14,438 shares of the conglomerate’s stock valued at $3,582,000 after acquiring an additional 50 shares during the period. Finally, Connolly Sarah T. grew its stake in Danaher by 0.5% during the third quarter. Connolly Sarah T. now owns 9,599 shares of the conglomerate’s stock valued at $2,382,000 after acquiring an additional 50 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Citigroup raised their price target on shares of Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Barclays boosted their target price on Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 10th. KeyCorp raised their price target on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Finally, Royal Bank of Canada boosted their price objective on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Six investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $268.27.

Insider Activity at Danaher

In other Danaher news, Director Teri List sold 3,289 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the sale, the director now owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares in the company, valued at $9,601,704. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Teri List sold 3,289 shares of the business’s stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the transaction, the director now owns 19,726 shares in the company, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Insiders sold 32,957 shares of company stock worth $8,265,802 in the last ninety days. 10.90% of the stock is owned by company insiders.

Danaher Stock Up 0.2 %

Shares of DHR opened at $236.08 on Tuesday. The firm has a market cap of $174.83 billion, a P/E ratio of 36.95, a P/E/G ratio of 3.95 and a beta of 0.83. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $259.00. The stock has a 50 day simple moving average of $248.72 and a two-hundred day simple moving average of $230.39. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company had revenue of $6.41 billion during the quarter, compared to analysts’ expectations of $6.10 billion. During the same quarter in the prior year, the company earned $2.87 EPS. The firm’s revenue was down 10.2% on a year-over-year basis. On average, analysts forecast that Danaher Co. will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.46%. The ex-dividend date is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is 16.90%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.